Abstract
We have known that endothelial nitric-oxide synthase (eNOS) and oxidative stress may play a key role in cardiac performance in failing rat hearts. However, the interactions between eNOS or oxidative stress and bradykinin (BK) under treatment of calcium channel blockers (CCBs) remain unknown. To elucidate the mechanism underlying the cardioprotective effect of long-acting dihydropyridine CCBs, we evaluated the effect of benidipine on the BK-eNOS and NAD(P)H oxidase pathway in Dahl salt-sensitive (DS) rats with heart failure. 11-week-old DS rats were treated with one of the following drug combinations for 7 weeks until the onset of the failing stage: vehicle, BK B2 receptor antagonist (FR172357 (FR)) alone, hydralazine, benidipine, and benidipine plus FR. The left ventricular end-systolic pressure-volume relationship (ESPVR) (contractility: Ees) was evaluated using a conductance catheter. Downregulated Ees and per cent of fractional shortening (%FS) assessed by echocardiography and eNOS expression in the failing stage were both significantly increased by using benidipine; this result was not found, however, when using FR alone or hydralazine or benidipine plus FR. Upregulated expression of NAD(P)H oxidase p22phox and p47phox and ...Continue Reading
References
Jul 1, 1985·The Journal of Clinical Investigation·T M McIntyreS M Prescott
Feb 1, 1996·Journal of Hypertension·K YoshidaK Abe
May 26, 1999·American Journal of Hypertension·N KobayashiH Matsuoka
Jun 29, 1999·British Journal of Pharmacology·C Bandeira-MeloM A Martins
Aug 13, 1999·Journal of Cardiovascular Pharmacology·N KobayashiH Matsuoka
Sep 10, 1999·The American Journal of Cardiology·X ZhangT H Hintze
Feb 26, 2000·Cardiovascular Research·N KobayashiH Matsuoka
Nov 21, 2001·Cardiovascular Drugs and Therapy·H AsanumaM Hori
Dec 12, 2001·Biochemical and Biophysical Research Communications·J L MehtaF Romeo
Mar 27, 2002·Circulation·Dan SorescuKathy K Griendling
Mar 27, 2002·Diabetologia·S JesminA Kitabatake
May 25, 2002·British Journal of Pharmacology·Biao XuAlbert Ferro
Aug 15, 2002·Cardiovascular Research·Naohiko KobayashiHiroaki Matsuoka
Oct 15, 2003·Hypertension·Naohiko KobayashiHiroaki Matsuoka
Dec 10, 2003·Circulation·Daniel TonduanguJin Bo Su
Jun 18, 2004·Journal of Hypertension·Naohiko KobayashiHiroaki Matsuoka
Jun 23, 2004·Lancet·Stevo JuliusUNKNOWN VALUE trial group
Jun 9, 2005·Journal of Hypertension·Jun SuzukiMasatsugu Horiuchi
Sep 21, 2005·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Masahiro MatsubaraKazuhide Hasegawa
Mar 1, 2006·Hypertension·Naohiko KobayashiHiroaki Matsuoka
Aug 31, 2006·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Toyofumi YoshiiMasatsugu Horiuchi
Citations
Oct 25, 2008·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·E M SeymourSteven F Bolling
Nov 16, 2011·Circulation Journal : Official Journal of the Japanese Circulation Society·Wataru KoguchiToshihiko Ishimitsu
Jun 16, 2012·Oxidative Medicine and Cellular Longevity·José Luis Miguel-CarrascoGuillermo Zalba
Apr 26, 2008·American Journal of Hypertension·Naohiko KobayashiHiroaki Matsuoka
Nov 29, 2008·American Journal of Hypertension·Naohiko KobayashiHiroaki Matsuoka
Sep 18, 2010·American Journal of Hypertension·Masaru IwaiMasatsugu Horiuchi
Nov 12, 2009·Journal of Cardiovascular Pharmacology·Hiromichi FukushimaToshihiko Ishimitsu
Nov 16, 2017·Clinical and Experimental Hypertension : CHE·Jeffrey YimSimon W Rabkin
Jul 1, 2020·Shock·Jianzhuo HeLiheng Guo